G. Boyea
Beaumont Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by G. Boyea.
Clinical Therapeutics | 2002
KimberlyK. Senter; Christine K. Mitchell; M Hardy; C. Flynn; M. Wallace; Linda Lewis; G. Boyea; Carol St. Henry; Jennifer Divo
tients demonstrated greater fatigue, pain, and appetite loss. One year after treatment, no statistically significant differences were demonstrated in either group. CONCLUSIONS: These results provide the first description of outcomes experienced by a group of patients who have undergone BCT and radiotherapy (either EBRT or BRACHY) for stage I or II breast cancer and been followed for up to 1 year. The results do not demonstrate that patients selected to receive a shorter treatment course with BRACHY had an increase in QOL. Quantitative research such as this study cannot be generalized to a larger population, and further studies are needed. ACKNOWLEDGMENTS: Special thanks to Drs. Peter Chen, Gary Gustafson, Jannifer Stromberg, Frank Vicini, and Alvaro Martinez of the Radiation Oncology Department for their assistance and support during the enrollment of patients in this study. The authors also acknowledge Mamtha Balasubramanian for her assistance in statistical analysis.
International Journal of Radiation Oncology Biology Physics | 2001
K.K. Senter; M Hardy; C. Flynn; Linda Lewis; M. Wallace; G. Boyea; C. Mitchell; L. Fluellen; C.St. Henry; A. Martinez
Abstract Purpose: The goal of this prospective, randomized study was to assess and compare compliance of patients diagnosed with prostate cancer to completing three different validated QOL instruments pre-treatment and six months later. Materials and Methods: Between April 2000 and April 2001, 124 patients were asked to fill out only one of three randomly selected QOL questionnaires (version A, B, C). Each addressed urinary and sexual function. One also addressed patients’ physical, social, family, emotional, and functional well being. Study patients received External Beam Radiation Therapy (EBRT) or Brachytherapy (BRACHY), according to departmental policy. Exclusion criteria included current/previous hormone therapy and prostatectomy. Patients were asked to return the questionnaire at their first treatment visit. The three tools were: A The Functional Assessment of Cancer Therapy for Prostate Patients (FACT-P), The Sexual Adjustments Questionnaire (SAQ), and The American Urological Association (AUA) Questionnaire. The Fact-P questionnaire elicits information about physical, social, family, emotional, and functional well being as they relate to prostate cancer. SAQ focuses on sexual function; the AUA on urinary symptoms. B SAQ and AUA only; identical to Version A, but does not address physical, social, family, emotional, and functional well-being. C The International Prostate Symptom Score (I-PSS) Questionnaire, which addresses urinary symptoms and Patient Sexual Function Questionnaire, which focuses on erectile function. Additionally, patients were asked to respond yes/no to four variables designed to evaluate these questionnaires: 1) ease of understanding, 2) too personal, 3)addresses concerns regarding urinary function and sexual potency and 4) willingness to complete questionnaire in six months. These variables were examined for any trends that may exist between the different questionnaires. Results: Fifteen (12%) of the 124 patients returned incomplete questionnaires due to the personal nature. When the 109 completed questionnaires were analyzed,the favorable responses of the four variables were compared. Favorable responses were received less frequently with version A when compared to version B (p=0.07) or Version C (p=0.08). Specifically, patients felt that version C addressed their concerns more effectively then version A (p= 0.03). Also, patients more frequently felt that version B was less personal when compared to versions A and C (p=0.01). When the patient responses were analyzed by treatment type, the group receiving EBRT appeared to trend toward version B. The group receiving BRACHY appeared to trend toward version C. Conclusion: Table I demonstrates that version B or C would provide a more effective QOL assessment. Patient accrual will continue to assess possible differences between B and C questionnaires. Evaluation Question Version A (n=35) Version B (n=35) Version C (n=39) 1. Easy to understand 86% yes 83% yes 95% yes 2.Too Personal 29% yes 14% yes 28% yes 3. Addresses Concerns 66% yes 77% yes 79% yes 4. Fill Out Again 80% yes 83% yes 85% yes Overall Favorable Responses 76% 82% 83%
International Journal of Radiation Oncology Biology Physics | 2007
C. Flynn; C. Mitchell; G. Boyea; Frank A. Vicini; A. Martinez
International Journal of Radiation Oncology Biology Physics | 2002
Linda Lewis; C. Flynn; G. Boyea; M. Wallace; K.K. Senter; M Hardy; A. Martinez
International Journal of Radiation Oncology Biology Physics | 2007
G. Boyea; J.V. Antonucci; M. Wallace; M. Ghilezan; G. Gustafson; Peter Y. Chen; K. Saputo; C. Flynn; A. Martinez
International Journal of Radiation Oncology Biology Physics | 2005
K. Saputo; A. Calcaterra; G. Boyea; M. Wallace; Mamtha Balasubramaniam; A. Martinez
Brachytherapy | 2009
Michel Ghilezan; Gary S. Gustafson; James Fontanesi; Peter Y. Chen; Daniel J. Krauss; Evelyn Sebastian; Leo A. Kim; Kim Marvin; M. Wallace; Amy Limbacher; K. McPhee; G. Boyea; A. Martinez
International Journal of Radiation Oncology Biology Physics | 2008
G. Boyea; C. Flynn; Mamtha Balasubramaniam; M. Wallace; F. Vicini; A. Martinez
International Journal of Radiation Oncology Biology Physics | 2010
J.M. Robertson; Mamtha Balasubramaniam; A. Calcaterra; M. Wallace; K. Marvin; G. Boyea; K. McPhee; A. Casey; M. Ghilezan; A. Martinez
Fuel and Energy Abstracts | 2010
K. A. Saputo; A. Calcaterra; Mahadevan Balasubramaniam; G. Boyea; Chris Flynn; Malcolm Wallace; M. Ghilezan; A. Martinez